Advertisement

Clinical Rheumatology

, Volume 38, Issue 12, pp 3595–3607 | Cite as

The effectiveness of treatments for Kashin–Beck disease: a systematic review and network meta-analysis

  • Kun Zou
  • Jinliang Hu
  • Qiao Zhou
  • Jiang Su
  • Birong Dong
  • Weiya ZhangEmail author
Original Article

Abstract

Objectives

This study aims to evaluate the efficacy of treatments for Kashin–Beck disease (KBD).

Method

We searched PubMed, Cochrane Central Register of Controlled Trials, Embase, Web of Science, SinoMed, Chinese National Knowledge Infrastructure, reference lists and published systematic reviews and registries of ongoing trials through May 2015 for randomised controlled trials (RCTs) of treatments for KBD. Outcomes of interest were pain, function, stiffness, overall clinical improvement, radiographic improvement (X-ray) and adverse events. Frequentist network meta-analyses were conducted using random-effects consistency model to assess the efficacy of treatments for KBD.

Results

Forty-four RCTs with 9815 participants were included in the review. In children or adolescents, selenium (risk ratio 1.88, 95% confidence interval (CI) 1.51–2.33), vitamin C (2.03, 1.40–2.95) and aspirin (2.14, 1.12–4.08) were effective for radiographic structure improvement. In adults, chondroitin plus glucosamine was the best for pain (standardised mean difference 1.46, 95% CI 1.07–1.85), followed by intra-articular injection of hyaluronic acid (IAH) (1.09, 0.70–1.48), chondroitin (0.84, 0.47–1.21), diclofenac (0.63, 1.18–1.08), naproxen (0.55, 0.12–0.98), meloxicam (0.52, 0.03–1.01) and glucosamine (0.40, 0.13–0.67) compared to placebo, with similar results for other clinical outcomes in adults. However, the strength of most evidence was limited by the small number of trials with low to moderate quality.

Conclusions

Selenium supplement has demonstrated some benefits for structural improvement of the disease in children. Chondroitin, glucosamine, IAH and nonsteroid anti-inflammatory drugs are effective for symptom improvements of KBD in adults. Evidence of surgical and complementary treatments for symptoms and aspirin and vitamin C for structure has yet to be established.

Key Points

• There were 23 nutraceuticals, pharmaceuticals and surgical and complementary treatments assessed for Kashin–Beck disease (KBD) in randomised trials.

• Among the 23 treatments, chondroitin, glucosamine, IAH and non-steroid anti-inflammatory drugs are more effective than placebo to relieve symptoms for adults with KBD.

• Selenium supplement is more effective than placebo for radiographic improvement in children or adolescents.

• The efficacy of surgeries, aspirin, vitamin C and complementary treatments for KBD has not been established yet.

Keywords

Beck disease Efficacy Kashin Network meta-analysis Randomised controlled trials Systematic review Treatments 

Notes

Contributors

KZ conceptualised and designed the study. KZ and JLH screened the literature and selected the study. KZ extracted data and accessed the quality of trials, conducted the analysis and wrote the draft of the manuscript. QZ wrote part of the discussion. WZ and BD advised on the analysis and the representation of the results. All authors contributed to the intellectual interpretation of the findings and approved the final manuscript.

Funding

QZ was supported by the Innovation Research Grant from the University of Electronic Science and Technology, Chengdu, China.

Compliance with ethical standards

Disclosures

None.

Supplementary material

10067_2019_4704_MOESM1_ESM.docx (293 kb)
ESM 1 (DOCX 292 kb)

References

  1. 1.
    Allander E (1994) Kashin-Beck disease. An analysis of research and public health activities based on a bibliography 1849-1992. Scand J Rheumatol Suppl 99:1–36CrossRefGoogle Scholar
  2. 2.
    Moreno-Reyes R, Suetens C, Mathieu F, Begaux F, Zhu D, Rivera MT, Boelaert M, Neve J, Perlmutter N, Vanderpas J (1998) Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status. N Engl J Med 339(16):1112–1120.  https://doi.org/10.1056/NEJM199810153391604 CrossRefPubMedGoogle Scholar
  3. 3.
    Utiger RD (1998) Kashin-Beck disease—expanding the spectrum of iodine-deficiency disorders. N Engl J Med 339(16):1156–1158.  https://doi.org/10.1056/NEJM199810153391611 CrossRefPubMedGoogle Scholar
  4. 4.
    Li D, Han J, Guo X, Qu C, Yu F, Wu X (2016) The effects of T-2 toxin on the prevalence and development of Kashin-Beck disease in China: a meta-analysis and systematic review. Toxicol Res 5(3):731–751.  https://doi.org/10.1039/C5TX00377F CrossRefGoogle Scholar
  5. 5.
    Yang L, Zhao GH, Yu FF, Zhang RQ, Guo X (2016) Selenium and iodine levels in subjects with Kashin-Beck disease: a meta-analysis. Biol Trace Elem Res 170(1):43–54.  https://doi.org/10.1007/s12011-015-0463-8 CrossRefPubMedGoogle Scholar
  6. 6.
    Chasseur C, Suetens C, Nolard N, Begaux F, Haubruge E (1997) Fungal contamination in barley and Kashin-Beck disease in Tibet. Lancet 350(9084):1074.  https://doi.org/10.1016/S0140-6736(05)70453-0 CrossRefPubMedGoogle Scholar
  7. 7.
    Suetens C, Moreno-Reyes R, Chasseur C, Mathieu F, Begaux F, Haubruge E, Durand MC, Neve J, Vanderpas J (2001) Epidemiological support for a multifactorial aetiology of Kashin-Beck disease in Tibet. Int Orthop 25(3):180–187CrossRefGoogle Scholar
  8. 8.
    Li L, Wang Q, Tian JH, Yang KH, Tian HL, Shi CH, Jiang J,  Wu TX, Liao YJ (2013) The relationship between the exposure and metabolism of iodine and Kaschin-Beck disease:a systematic review. Chinese Journal of Evidence-Based Pediatrics: 176–180 [In Chinese]. https://www.cjebp.net/CN/abstract/abstract9054.html
  9. 9.
    Yao Y, Pei F, Kang P (2011) Selenium, iodine, and the relation with Kashin-Beck disease. Nutrition 27(11-12):1095–1100.  https://doi.org/10.1016/j.nut.2011.03.002 CrossRefPubMedGoogle Scholar
  10. 10.
    Wang Y, Yang Z, Gilula LA, Zhu C (1996) Kashin-Beck disease: radiographic appearance in the hands and wrists. Radiology 201(1):265–270.  https://doi.org/10.1148/radiology.201.1.8816556 CrossRefPubMedGoogle Scholar
  11. 11.
    Mathieu F, Begaux F, Lan ZY, Suetens C, Hinsenkamp M (1997) Clinical manifestations of Kashin-Beck disease in Nyemo Valley, Tibet. Int Orthop 21(3):151–156CrossRefGoogle Scholar
  12. 12.
    Wang FQ, Wang ZW, Ping ZG, Guo X (2005) Epidemiological investigation of the declined prevalence of Kashin-Beck disease in Linyou County, Shaanxi Province, China. Chin J Endemiol 06:637–638 [in Chinese]Google Scholar
  13. 13.
    Li FZ, Deng JY, Yang RM, Li DW, Ma GJ, Liao P, Hou CH, Zheng YT, Zhang L, Wu G (2006) Investigating report on prevalence rate of Kaschin-Beck disease in adults in Sichuan Province in 2005. Endemic Dis Bull 01:23–25 [in Chinese]Google Scholar
  14. 14.
    Sun L-Y, Yuan L-J, Fu Y, Deng J-Y, Wang L-H (2012) Prevalence of Kaschin-Beck disease among Tibetan children in Aba Tibetan and Qiang Autonomous Prefecture: a 3-year epidemiological survey. World J Pediatr 8(2):140–144.  https://doi.org/10.1007/s12519-012-0351-7 CrossRefPubMedGoogle Scholar
  15. 15.
    Tomlinson R (1999) Beijing conference reviews Kashin-Beck disease. BMJ 318(7182):485CrossRefGoogle Scholar
  16. 16.
    Jirong Y, Huiyun P, Zhongzhe Y, Birong D, Weimin L, Ming Y, Yi S (2012) Sodium selenite for treatment of Kashin-Beck disease in children: a systematic review of randomised controlled trials. Osteoarthr Cartil 20(7):605–613.  https://doi.org/10.1016/j.joca.2012.02.012 CrossRefPubMedGoogle Scholar
  17. 17.
    Yu FF, Xia CT, Fang H, Han J, Younus MI, Guo X (2014) Evaluation of the therapeutic effect of treatment with intra-articular hyaluronic acid in knees for Kashin-Beck disease: a meta-analysis. Osteoarthr Cartil 22(6):718–725.  https://doi.org/10.1016/j.joca.2014.04.012 CrossRefPubMedGoogle Scholar
  18. 18.
    Mills EJ, Thorlund K, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914.  https://doi.org/10.1136/bmj.f2914 CrossRefPubMedGoogle Scholar
  19. 19.
    General office of endemic disease control, People’s Republic of China (1983) X-ray criteria of treatment effect on Kashin-beck disease (trial)Google Scholar
  20. 20.
    Ministry of Health, People’s Republic of China (1996) The judging of treatment effect on Kashin-beck disease (WS/T 79-1996)Google Scholar
  21. 21.
    Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394.  https://doi.org/10.1016/j.jclinepi.2010.04.026 CrossRefPubMedGoogle Scholar
  22. 22.
    Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH, Group GW (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630.  https://doi.org/10.1136/bmj.g5630 CrossRefPubMedGoogle Scholar
  23. 23.
    Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS One 8(10):e76654.  https://doi.org/10.1371/journal.pone.0076654 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    White IR (2015) Network meta-analysis. Stata J 15(4):951–985CrossRefGoogle Scholar
  25. 25.
    Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683–691CrossRefGoogle Scholar
  26. 26.
    Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29(7-8):932–944.  https://doi.org/10.1002/sim.3767 CrossRefPubMedGoogle Scholar
  27. 27.
    Higgins JPT, Green S (editors) (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http://www.cochrane-handbook.org/.
  28. 28.
    da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Juni P, Trelle S (2016) Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 387(10033):2093–2105.  https://doi.org/10.1016/S0140-6736(16)30002-2 CrossRefPubMedGoogle Scholar
  29. 29.
    Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18(4):476–499.  https://doi.org/10.1016/j.joca.2010.01.013 CrossRefGoogle Scholar
  30. 30.
    Vane JR, Botting RM (1998) Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 104(3A):2S–8S discussion 21S-22SCrossRefGoogle Scholar
  31. 31.
    Monfort J, Pelletier JP, Garcia-Giralt N, Martel-Pelletier J (2008) Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 67(6):735–740.  https://doi.org/10.1136/ard.2006.068882 CrossRefPubMedGoogle Scholar
  32. 32.
    Henrotin Y, Mobasheri A, Marty M (2012) Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther 14(1):201.  https://doi.org/10.1186/ar3657 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ (2015) Chondroitin for osteoarthritis. Cochrane Database Syst Rev 1:CD005614.  https://doi.org/10.1002/14651858.CD005614.pub2 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev (2):CD002946.  https://doi.org/10.1002/14651858.CD002946.pub2
  35. 35.
    Zou K, Wong J, Abdullah N, Chen X, Smith T, Doherty M, Zhang W (2016) Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 75(11):1964–1970.  https://doi.org/10.1136/annrheumdis-2015-208387 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Trigkilidas D, Anand A (2013) The effectiveness of hyaluronic acid intra-articular injections in managing osteoarthritic knee pain. Ann R Coll Surg Engl 95(8):545–551.  https://doi.org/10.1308/003588413X1362996004943210.1308/rcsann.2013.95.8.545
  37. 37.
    Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2):CD005321.  https://doi.org/10.1002/14651858.CD005321.pub2
  38. 38.
    Xie DM, Wang RH, Liao YL, Xu L, Yue JR, Deng CY (2016) Selenium supplement for Kashin-Beck disease: a network meta-analysis. Chin J Evid Based Med 16(11):1284–1290 [in Chinese].  https://doi.org/10.7507/1672-2531.20160195 CrossRefGoogle Scholar
  39. 39.
    Zou K, Liu G, Wu T, Du L (2009) Selenium for preventing Kashin-Beck osteoarthropathy in children: a meta-analysis. Osteoarthr Cartil 17(2):144–151.  https://doi.org/10.1016/j.joca.2008.06.011 CrossRefPubMedGoogle Scholar
  40. 40.
    Quan W, Xiu-xia L, Lun L, Jin-hui T, Ke-hu Y, Tai-xiang W, Yong-jian L (2013) Correlation between selenium and Kaschin-Beck disease. Chin J Evid Based Med 13(12):1421–1430Google Scholar
  41. 41.
    Han J, Wang W, Qu C, Liu R, Li W, Gao Z, Guo X (2015) Role of inflammation in the process of clinical Kashin-Beck disease: latest findings and interpretations. Inflamm Res 64(11):853–860.  https://doi.org/10.1007/s00011-015-0861-6 CrossRefPubMedGoogle Scholar
  42. 42.
    Roach JE, Tomblin W, Eyring EJ (1975) Comparison of the effects of steroid, aspirin and sodium salicylate on articular cartilage. Clin Orthop Relat Res 106:350–356CrossRefGoogle Scholar
  43. 43.
    Wluka AE, Ding C, Wang Y, Jones G, Urquhart DM, Cicuttini FM (2015) Aspirin is associated with reduced cartilage loss in knee osteoarthritis: data from a cohort study. Maturitas 81(3):394–397.  https://doi.org/10.1016/j.maturitas.2015.04.015 CrossRefPubMedGoogle Scholar
  44. 44.
    Manicourt DH, Druetz-Van Egeren A, Haazen L, Nagant de Deuxchaisnes C (1994) Effects of tenoxicam and aspirin on the metabolism of proteoglycans and hyaluronan in normal and osteoarthritic human articular cartilage. Br J Pharmacol 113(4):1113–1120CrossRefGoogle Scholar
  45. 45.
    Canter PH, Wider B, Ernst E (2007) The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. Rheumatology 46(8):1223–1233.  https://doi.org/10.1093/rheumatology/kem116 CrossRefPubMedGoogle Scholar
  46. 46.
    Rosenbaum CC, O’Mathuna DP, Chavez M, Shields K (2010) Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. Altern Ther Health Med 16(2):32–40PubMedGoogle Scholar
  47. 47.
    Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, Egger M, Juni P (2010) Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 341:c3515.  https://doi.org/10.1136/bmj.c3515 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Chen ZL, Ma JM (1979) “Aspirin for Kashin-Beck disease: A preliminary observation on the efficacy.” Medical Journal of Chinese People’s Liberation Army(02):128. [in Chinese] Google Scholar
  49. 49.
    Niu GH, Zhang BZ, Hou SF (1990) The effect of half dose of selenium supplementation on prevention and treatment of Kaschin Beck disease Chinese Journal of Endemic Diseases 9(2):99–100 [in Chinese] Google Scholar
  50. 50.
    Moreno-Reyes R, Mathieu F, Boelaert M, Begaux F, Suetens C, Rivera MT, Nève J, Perlmutter N, Vanderpas J (2003) Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. Am J Clin Nutr 78(1):137–144CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Kun Zou
    • 1
  • Jinliang Hu
    • 2
  • Qiao Zhou
    • 3
  • Jiang Su
    • 3
  • Birong Dong
    • 4
  • Weiya Zhang
    • 5
    Email author
  1. 1.West China Research Centre of Rural Health Development, Department of Health Policy and Management, West China School of Public Health, West China Forth HospitalSichuan UniversityChengduChina
  2. 2.Institution of Health Policy and Hospital Management, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s HospitalAffiliated Hospital of the University of Electronic Science and TechnologyChengduChina
  3. 3.Department of Rheumatology and Immunology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s HospitalAffiliated Hospital of the University of Electronic Science and TechnologyChengduChina
  4. 4.Centre of Gerontology and Geriatrics, West China Hospital, West China School of MedicineSichuan UniversityChengduChina
  5. 5.Academic Rheumatology, Division of Rheumatology, Orthopedics and Dermatology, School of Medicine, Nottingham City HospitalUniversity of NottinghamNottinghamUK

Personalised recommendations